ITRM Iterum Therapeutics plc
USHealthcareAs of 2026-03-31 16:00
Why ITRM matters now
Iterum Therapeutics plc (ITRM) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.03 with -10.98% on the session and $1.6M in market capitalization; recent performance reads 1-month -57.14% and YTD -91.04%.
The latest financial table shown here is Q3 2025, with revenue of $390.0K, net income of $-9.0M, and EPS of $-0.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1068.5%.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.22
P/S
4.78
EV/EBITDA
-1.07
DCF Value
$-1.10
FCF Yield
-1068.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-171.3%
Operating Margin
-5202.8%
Net Margin
-6913.1%
ROE
602.4%
ROA
-82.9%
ROIC
-77.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $390.0K | $-9.0M | $-0.20 |
| Q2 2025 | $0.00 | $-6.5M | $-0.16 |
| Q1 2025 | $0.00 | $-4.9M | $-0.14 |
| Q4 2024 | $0.00 | $-6.6M | $-0.25 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IE
Exchange
—
Beta
3.01
Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.